Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections.
M G Netea, … , A F Stalenhoef, J W van der Meer
M G Netea, … , A F Stalenhoef, J W van der Meer
Published March 15, 1996
Citation Information: J Clin Invest. 1996;97(6):1366-1372. https://doi.org/10.1172/JCI118556.
View: Text | PDF
Research Article Article has an altmetric score of 20

Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections.

  • Text
  • PDF
Abstract

Lipoproteins can bind lipopolysaccharide (LPS) and decrease the LPS-stimulated production of pro-inflammatory cytokines. We investigated the effect of increased plasma concentrations of low-density-lipoproteins (LDL) on survival and cytokine production after a lethal challenge with either LPS or live Gram-negative bacteria in LDL receptor deficient mice (LDLR-/-). The LDLR-/- mice challenged with LPS had an eightfold increased LD50 when compared with the wild type controls (C57Bl/6J), while tumor necrosis factor alpha (TNFalpha) and interleukin-1 alpha (IL-1 alpha) plasma concentrations were decreased twofold. LDLR-/- mice had significantly lower and delayed mortality than control mice after infection with Klebsiella pneumoniae. No differences in the outgrowth of bacteria in the organs were present between the two groups, while circulating cytokine concentrations were decreased twofold in LDLR-/- mice. In contrast, the LPS-stimulated in vitro production of cytokines by peritoneal macrophages of LDLR-/- mice was significantly increased compared with controls. This increase was associated with enhanced specific binding of LPS to the macrophages of LDLR-/- mice. In conclusion, endogenous LDL can protect against the lethal effects of endotoxin and Gram-negative infection. At least part of this protection is achieved through decreased in vivo production of pro-inflammatory cytokines, in spite of increased cytokine production capacity.

Authors

M G Netea, P N Demacker, B J Kullberg, O C Boerman, I Verschueren, A F Stalenhoef, J W van der Meer

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 Total
Citations: 4 3 4 4 5 4 5 1 2 6 3 3 2 4 4 8 4 5 10 6 10 7 10 6 7 11 5 7 4 1 155
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2011 (4)

Title and authors Publication Year
Advances in Clinical Chemistry
M Mahler
Advances in Clinical Chemistry Volume 54 2011
More than Inflammation: Interleukin-1β Polymorphisms and the Lipid Metabolism
MG Netea, CA Dinarello
The Journal of clinical endocrinology and metabolism 2011
TLR1/TLR2 Heterodimers Play an Important Role in the Recognition of Borrelia Spirochetes
M Oosting, HT Hofstede, P Sturm, GJ Adema, BJ Kullberg, JW van der Meer, MG Netea, LA Joosten
PloS one 2011
Human visceral leishmaniasis: decrease in serum cholesterol as a function of splenic parasite load
J Ghosh, CS Lal, K Pandey, VN Das, P Das, K Roychoudhury, S Roy
Annals of Tropical Medicine and Parasitology 2011

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 19 X users
Referenced in 3 patents
On 1 Facebook pages
Referenced in 1 Wikipedia pages
Reddited by 1
56 readers on Mendeley
See more details